

LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma

Takehito Ehara

Shinsung University

Takeshi Uehara (✉ tuehara@shinshu-u.ac.jp)

Shinshu University School of Medicine <https://orcid.org/0000-0002-7694-9015>

Tomoyuki Nakajima

Shinshu Daigaku

Yasuhiro Kinugawa

Shinshu Daigaku

Shota Kobayashi

Shinshu Daigaku

Mai Iwaya

Shinshu Daigaku

Hiroyoshi Ota

Shinshu Daigaku

Yuji Soejima

Shinshu Daigaku

Research article

Keywords: leucine-rich repeat-containing G-protein-coupled receptor 5, poorly differentiated gastric adenocarcinoma, RNA in situ hybridization

Posted Date: July 22nd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-27693/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Cancer on March 6th, 2021. See the published version at <https://doi.org/10.1186/s12885-021-07913-6>.

Abstract

Background Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is an important cancer stem cell marker in gastric cancer. However, no detailed studies are available on LGR5 expression in poorly differentiated gastric adenocarcinoma (PD-AC). Therefore, we investigated the relationship between LGR5 expression and clinicopathological data in PD-AC. Methods LGR5 expression was identified in 41 PD-AC cases using RNAscope, which is a highly sensitive RNA in situ hybridization method. Epstein–Barr virus (EBV) infection was also detected by EBV in situ hybridization. Results LGR5 expression was identified in 38 of 41 PD-AC cases, and 17 cases were identified as LGR5 high. The frequency of EBV positivity tended to be higher in the LGR5 -low group than in the LGR5 -high group ($P=0.0764$). Furthermore, the frequency of vascular invasion tended to be higher in the LGR5 -high group than in the LGR5 -low group ($P=0.0764$). The overall survival of PD-AC patients in the LGR5 -high group was significantly lower than in the LGR5 -low group (log-rank test, $P=0.0108$). The Cox proportional hazard regression model revealed that the LGR5 -low group (HR=0.29; 95% CI: 0.11–0.74; $P=0.01$) showed independently better OS for PD-AC. Conclusions The correlation between high LGR5 expression and poor prognosis in PD-AC may be applicable to the development of LGR5 targeted therapy and prognostic markers. Further study is warranted.

Background

Although the incidence of gastric cancer is decreasing, many individuals develop the disease. Gastric cancer is the fifth most frequent cancer and the third leading cause of cancer death [1]. Various treatment methods for gastric cancer, including surgery, radiation, and chemotherapy, have been performed. Among them, many recent studies have been conducted on cancer stem cells (CSCs), which are present in tumor tissues, and anti-CSC therapies have shown promising results [2]. CSCs are resistant to radiation and chemotherapy, and residual CSCs contribute to tumor regrowth. Therefore, effective anti-CSC therapy should be administered in combination with existing methods, such as chemotherapy and radiotherapy [3]. Some reports have investigated gastric CSCs, which typically express CD44, CD133, and Musashi-1 [4]. Additionally, leucine-rich repeat-containing G-protein-coupled receptor 5 (*LGR5*) was identified as a potential robust CSC marker in gastric cancer using a new method [5] [6].

The standard treatment for stage I gastric cancer is curative resection only, and it is associated with an excellent prognosis [7]. On the other hand, the standard treatment for stage II/III gastric cancer is curative resection and adjuvant chemotherapy, but the frequency of recurrence is high [8]. Therefore, it is necessary to improve the prognosis of stage II/III gastric cancer patients. Furthermore, the components of poorly differentiated cancer tissues also have a significant impact on prognosis. In gastric cancer, poorly differentiated adenocarcinoma (PD-AC) has a poor prognosis [9], but the underlying mechanisms remain unclear. Additionally, the expression of CSC markers in poorly differentiated gastric cancer, especially *LGR5*, has not been reported. Therefore, we investigated the clinicopathological relationship between *LGR5* marker expression and prognosis in stage II/III gastric cancer patients.

Methods

Patients and materials

We identified 91 PD-AC cases who underwent surgical resection between 2008 and 2018 at six institutes [Shinshu University Hospital (Matsumoto, Japan), Nagano Municipal Hospital (Nagano, Japan), Aizawa Hospital (Matsumoto, Japan), Showa Inan General Hospital (Komagane, Japan), Iida Municipal Hospital (Iida, Japan), and Nagano Matsushiro General Hospital (Nagano, Japan)] and evaluated their clinicopathological features. Of these patients, stage II and III cases were selected. A re-evaluation by two pathologists (T.U. and H.O.) before analysis excluded five cases that did not contain poorly differentiated components, and 41 cases remained as candidates for analysis. This study was approved by the Ethics Committee of Shinshu University, Japan (no. 4088).

Histopathology, immunohistochemical staining, and evaluation

Paraffin blocks fixed with 8% formaldehyde containing sufficient tumor for analysis were prepared for hematoxylin and eosin (HE) staining and tissue microarray (TMA) analysis by extracting a core with a diameter of 3 mm from each case. Additionally, the TMA was subjected to immunostaining using antibodies against the following mismatch repair proteins (MMRPs): MLH1 (ES05; mouse monoclonal; dilution 1:50), PMS2 (EP51; rabbit monoclonal; dilution 1:40), MSH2 (FE11; mouse monoclonal; dilution 1:50), or MSH6 (EP49; rabbit monoclonal; dilution 1:50; Agilent Technologies, Santa Clara, CA, USA), as described previously [10]. As reported in our previous paper, the staining results were scored as positive when a nuclear staining pattern was observed. If at least one of the four antibodies did not show expression, MMR protein deficiency was indicated. In the tumor, the tumor-infiltrating lymphocyte (TIL) score was assessed using a four-tier scale and recorded as follows: none: 0; mild: 1; moderate: 2; and marked: 3 [11]. The TIL score was classified as low grade (scores 0 and 1) and high grade (2 and 3).

EBER *in situ* hybridization

The EBER *in situ* hybridization assay was performed on TMA block sections. Epstein–Barr virus (EBV) was identified using EBER probes (ISH iVIEW Blue detection kit; Ventana Medical Systems Inc., Oro Valley, AZ, USA).

LGR5 RNA *in situ* hybridization

LGR5 mRNA detection was performed using the RNAscope® kit (Advanced Cell Diagnostics, Hayward, CA, USA), as described previously [10]. Additionally, a four-step evaluation method we reported previously was used [10]. Furthermore, LGR5 mRNA expression was categorized as low expression (grades 0, 1+, 2+,

and 3+) and high expression (4+). We analyzed the relationship between *LGR5* expression and the clinicopathological data and prognosis in patients with PD-AC, particularly regarding overall survival (OS).

Statistical analysis

The chi-squared test was applied to assess statistical significance. A P-value < 0.05 was considered to be statistically significant. The OS rates of PD-AC patients were calculated using the Kaplan–Meier method, and differences were compared using the log-rank test. Univariate and multivariate analyses for prognostic factors were performed using the Cox proportional hazard regression model. A P-value <0.05 was considered to be statistically significant. Statistical analysis was performed using JMP version 13 (SAS Institute Japan, Tokyo, Japan).

Results

LGR5 expression in PD-AC

In PD-AC patients, 38 of 41 cases showed *LGR5* expression. Among them, 17 cases were identified as *LGR5* high (Fig. 1A and 1B). Moreover, *LGR5* expression was completely absent in three cases (Fig. 1D and 1E). *LGR5* expression varied from diffuse to scattered.

Relationship between *LGR5* expression and clinicopathological characteristics

EBER expression was negative in most cases (Fig. 1C). Although there were few EBV-positive PD-AC cases (Fig. 1F), all exhibited low *LGR5* expression. *LGR5* expression and clinicopathologic data are shown in Table 1. The number of EBV-positive PD-AC cases tended to be higher in the *LGR5*-low expression group than in the *LGR5*-high expression group (P=0.0764). The frequency of vascular invasion tended to be higher in the *LGR5*-high expression group than in the *LGR5*-low expression group (P=0.0764). No significant difference was found between the *LGR5*-high expression group and *LGR5*-low expression group regarding TILs, MSI, histological subtype, or TNM stage.

Prognostic value of *LGR5* in PD-AC

The prognostic value of *LGR5* expression in PD-AC was analyzed by the Kaplan–Meier method and log-rank test (Fig. 2). The median OS for the study patients was 1,146 (range; 635.5–1718) days. A significant difference was found in OS between PD-AC cases in the *LGR5*-high expression group [median OS: 756 (range; 154.5–1306.5) days] and *LGR5*-low expression group [median OS: 1338 (range; 922.75–2022.75) days] (log-rank test, P=0.0108).

We evaluated the relationship between clinicopathological factors and *LGR5* expression regarding OS using a Cox proportional hazard regression model (Table 2), which revealed that the *LGR5*-low expression group (HR = 0.29; 95% CI: 0.11–0.74; P= 0.01) had independently better OS for PD-AC.

Discussion

LGR5 is an independent prognostic factor in PD-AC stages II and III. Although PD-AC has a poor prognosis [9], the related factors are not well understood. PD-AC exists as solid and non-solid subtypes. The prognosis of patients with the non-solid subtype with fibrosis is poor [12]. In our study, most PD-AC cases were non-solid, but no clear difference was observed in the prognosis of both non-solid and solid subtypes. *LGR5* is also a promising gastric CSC marker, and high *LGR5* expression in the poor prognosis group may suggest an involvement of CSCs in determining the prognosis. Therefore, *LGR5* may be a therapeutic target in PD-AC and improve PD-AC patient prognoses.

Migration ability and epithelial-mesenchymal transition (EMT) are increased in poorly differentiated gastric cancer [13]. Therefore, the poor prognosis of patients with high *LGR5* expression may be related to the histological features of poorly differentiated cancer represented by enhanced migration ability, EMT-related protein expression, and *LGR5* expression. Cancer cell migration is known to affect prognosis in gastric cancer [13]. Additionally, *LGR5* expression, although not in the stomach, is related to migration ability and EMT [14]. In our study, the correlation between vascular invasion and high *LGR5* expression may support an association of *LGR5* expression with EMT. High *LGR5* expression and EMT were reported to be correlated in gastric cancer [15]. Furthermore, Zhang et al. reported that the *LGR5* ligand *RSPO2* promotes EMT in gastric cancer cells by activating WNT/ β -catenin signaling via *LGR5* [16]. Therefore, elucidation of the relationship between *LGR5* and *RSPO2* in PD-AC may lead to the development of new therapeutic methods and an improved prognosis for PD-AC.

Although some reports have indicated that high *LGR5* expression is associated with a poor prognosis [17] [18], others have reported that high *LGR5* expression correlates with a good prognosis using RNAscope, which is considered to have high reliability [19] [20]. *LGR5* expression in the tumors of various organs has been widely investigated, mainly using immunostaining. However, the results of immunostaining may be controversial and uncertain. We previously reported that high *LGR5* expression might be a poor prognostic factor in breast cancer by RNAscope examination [21]. Further studies are needed regarding the prognostic impact of *LGR5* RNA expression.

Several reports have investigated *LGR5* expression in gastric cancer. One indicated no significant difference in the OS of gastric cancer patients when examined using RNAscope [22]. Although evaluated by immunostaining, *LGR5* overexpression was reported to be significantly associated with an increased risk of death in gastric cancer patients in a review of *LGR5* expression in gastric cancer [23]. In addition, Bu *et al.* reported that *LGR5* expression is associated with a favorable prognosis, although this was limited to stages I and II [24]. Furthermore, *LGR5* expression was associated with a high stage and lymph node metastasis [22]. Although no association was observed between high *LGR5* expression and the

histological type, as pointed out in a previous review [22], Xi *et al.* reported that high *LGR5* expression is associated with poorly differentiated cancer [25]. However, Bu *et al.* reported that *LGR5* is highly expressed in well-differentiated cancer [24]. Additionally, in studies using RNAscope, high *LGR5* expression is correlated with well-differentiated cancer [26]. However, there is no comparison between *LGR5* expression and prognosis in PD-AC using RNAscope, and the association between high *LGR5* expression and poor prognosis in poorly differentiated cancer is a new finding.

The tendency for low *LGR5* expression in EBV-positive tumors may be a feature of EBV-associated gastric cancer. According to a novel molecular pathological classification [27], EBV-associated gastric cancer is recognized as a distinct type of gastric cancer with a good prognosis [28]. The Cancer Genome Atlas Research Network reports that gastric cancer is divided into four types [27]. Therefore, to accumulate further knowledge in the future, it is necessary to analyze *LGR5* expression in each type.

Our study has some limitations. This study included a relatively small sample size, which may have led to unreliable estimates. *LGR5* expression and migration must be investigated in cultured cells; additionally, *LGR5* expression must be analyzed in EBV-infected cells.

Conclusions

The association of *LGR5* expression and patient prognosis in poorly differentiated gastric cancer may be applicable to the development of *LGR5* targeted therapy and prognostic markers, but further study is desired.

Abbreviations

CSC: cancer stem cell; *LGR5*: leucine-rich repeat-containing G-protein-coupled receptor 5; PD-AC: poorly differentiated adenocarcinoma; TMA: tissue microarray; TILs: tumor-infiltrating lymphocytes; OS: overall survival; EMT: epithelial-mesenchymal transition.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Shinshu University School of Medicine (Approval Code: 4088). The requirement of informed consent was waived, and an opt-out method was used because of the retrospective design of the study. The investigation was conducted in compliance with the Helsinki Declaration.

Consent for publication

Not applicable.

Availability of data and materials

All data generated and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was partially supported by the Hokuto Foundation for Bioscience (grant awarded to T.U.). The funding body had no role in the study design, collection, analysis, or interpretation of data or manuscript writing. The authors declare no conflicts of interest.

Authors' contributions

TE participated in the design of the study, performed the pathological analysis, and drafted the manuscript. TU, SK, and MI helped with the pathological analysis. TU performed the statistical analysis. TN and YK conducted immunohistochemistry. TE and US examined the clinical data of cases. HO and TU critically revised the draft for important intellectual content. All authors have read and approved the manuscript.

Acknowledgments

We are grateful to Yukihiro Kobayashi, Masanobu Momose, Yasuyo Shimojo, Naoko Ogiwara, Akiko Inamura, Chitoshi Arai, Yasuhiro Kinugawa, Marina Nuno, Kanade Wakabayashi, Naoko Yamaoka, and Tomoya Hachisu at Shinshu University Hospital for their excellent technical assistance. We thank Nicole Okoh, PhD, and Melissa Crawford, PhD, from Edanz Group (<https://en-author-services.edanzgroup.com/ac>) for editing a draft of this manuscript.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA

Cancer J Clin. 2018.

2. Bekaii-Saab T, El-Rayes B Identifying and targeting cancer stem cells in the treatment of gastric cancer. *Cancer*. 2017;123:1303-1312.
3. Brungs D, Aghmesheh M, Vine KL, Becker TM, Carolan MG, Ranson M Gastric cancer stem cells: evidence, potential markers, and clinical implications. *Journal of gastroenterology*. 2016;51:313-326.
4. Wang T, Ong CW, Shi J, Srivastava S, Yan B, Cheng CL et al. Sequential expression of putative stem cell markers in gastric carcinogenesis. *Br J Cancer*. 2011;105:658-665.
5. Li XB, Yang G, Zhu L, Tang YL, Zhang C, Ju Z et al. Gastric Lgr5(+) stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice. *Cell Res*. 2016;26:838-849.
6. Leushacke M, Tan SH, Wong A, Swathi Y, Hajamohideen A, Tan LT et al. Lgr5-expressing chief cells drive epithelial regeneration and cancer in the oxyntic stomach. *Nature cell biology*. 2017;19:774-786.
7. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H Gastric cancer. *Lancet*. 2016;388:2654-2664.
8. Nakagawa N, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K et al. Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multi-institutional dataset. *Cancer Med*. 2018;7:6020-6029.
9. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. *Cancer*. 2000;89:1418-1424.
10. Nakajima T, Uehara T, Iwaya M, Kobayashi Y, Maruyama Y, Ota H Characterization of LGR5 expression in poorly differentiated colorectal carcinoma with mismatch repair protein deficiency. *BMC Cancer*. 2020;20:319.
11. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. *J Pathol*. 1997;182:318-324.
12. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA et al. Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. *Anticancer Res*. 2006;26:639-646.
13. Ueta K, Otowa Y, Kakeji Y, Hirashima M PROX1 Is Associated with Cancer Progression and Prognosis in Gastric Cancer. *Anticancer Res*. 2018;38:6139-6145.
14. Zhang J, Cai H, Sun L, Zhan P, Chen M, Zhang F et al. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/beta-catenin pathway and predicts poor survival of glioma patients. *J Exp Clin Cancer Res*. 2018;37:225.
15. Du M, Zhuang Y, Tan P, Yu Z, Zhang X, Wang A microRNA-95 knockdown inhibits epithelial-mesenchymal transition and cancer stem cell phenotype in gastric cancer cells through MAPK pathway by upregulating DUSP5. *J Cell Physiol*. 2020;235:944-956.
16. Zhang H, Han X, Wei B, Fang J, Hou X, Lan T et al. RSP02 enhances cell invasion and migration via the WNT/beta-catenin pathway in human gastric cancer. *J Cell Biochem*. 2019;120:5813-5824.

17. Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M et al. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. *Annals of surgical oncology*. 2011;18:1166-1174.
18. Chen W, Fu Q, Fang F, Fang J, Zhang Q, Hong Y Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 predicts poor prognosis in hepatocellular carcinoma. *Saudi J Biol Sci*. 2018;25:904-908.
19. Martin ML, Zeng Z, Adileh M, Jacobo A, Li C, Vakiani E et al. Logarithmic expansion of LGR5(+) cells in human colorectal cancer. *Cell Signal*. 2018;42:97-105.
20. Kuraishi Y, Uehara T, Kobayashi Y, Nakajima T, Watanabe T, Shimizu A et al. Correlation of clinicopathological features and leucine-rich repeat-containing G-protein-coupled receptor 5 expression in pancreatic ductal adenocarcinoma. *Pathol Res Pract*. 2019;215:152623.
21. Ogasawara S, Uehara T, Nakajima T, Iwaya M, Maeno K, Tsuchiya S et al. Correlation of clinicopathological features and LGR5 expression in triple-negative breast cancer. *Ann Diagn Pathol*. 2020;46:151491.
22. Jang BG, Lee BL, Kim WH Prognostic significance of leucine-rich-repeat-containing G-protein-coupled receptor 5, an intestinal stem cell marker, in gastric carcinomas. *Gastric Cancer*. 2016;19:767-777.
23. Huang T, Qiu X, Xiao J, Wang Q, Wang Y, Zhang Y et al. The prognostic role of Leucine-rich repeat-containing G-protein-coupled receptor 5 in gastric cancer: A systematic review with meta-analysis. *Clin Res Hepatol Gastroenterol*. 2016;40:246-253.
24. Bu Z, Zheng Z, Zhang L, Li Z, Sun Y, Dong B et al. LGR5 is a promising biomarker for patients with stage I and II gastric cancer. *Chin J Cancer Res*. 2013;25:79-89.
25. Xi HQ, Cai AZ, Wu XS, Cui JX, Shen WS, Bian SB et al. Leucine-rich repeat-containing G-protein-coupled receptor 5 is associated with invasion, metastasis, and could be a potential therapeutic target in human gastric cancer. *Br J Cancer*. 2014;110:2011-2020.
26. Jang BG, Lee BL, Kim WH Distribution of LGR5+ cells and associated implications during the early stage of gastric tumorigenesis. *PLoS One*. 2013;8:e82390.
27. Cancer Genome Atlas Research N Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014;513:202-209.
28. Liu X, Liu J, Qiu H, Kong P, Chen S, Li W et al. Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis. *BMC Cancer*. 2015;15:782.

Tables

Table 1 *LGR5* expression and clinicopathological characteristics in PD-AC

| Factors | n | <i>LGR5</i> expression | | P-value |
|---------------------|----|------------------------|------------|---------|
| | | High (n=17) | Low (n=24) | |
| Age | | | | 0.0472 |
| >74 years | 19 | 11 | 8 | |
| ≤ 74 years | 22 | 6 | 16 | |
| Sex | | | | 0.0498 |
| Male | 24 | 13 | 11 | |
| Female | 17 | 4 | 13 | |
| EBV | | | | 0.0764 |
| Positive | 4 | 0 | 4 | |
| Negative | 37 | 17 | 20 | |
| Vascular invasion | | | | 0.0764 |
| Present | 37 | 17 | 20 | |
| Absent | 4 | 0 | 4 | |
| TIL | | | | 0.283 |
| High | 25 | 9 | 16 | |
| Low | 16 | 8 | 8 | |
| MSI | | | | 0.2176 |
| Present | 19 | 10 | 9 | |
| Absent | 21 | 7 | 14 | |
| Differentiated-type | | | | 0.2921 |
| Solid-type 1 | 8 | 2 | 6 | |
| Non-solid-type 2 | 33 | 15 | 18 | |
| TNM stage | | | | 0.9382 |
| II | 19 | 8 | 11 | |
| III | 22 | 9 | 13 | |

Table 2 Univariate and multivariate analyses of prognostic factors for PD-AC

| Factors | Univariate analysis | | Multivariate analysis | |
|--------------------------------------|---------------------|---------|-----------------------|---------|
| | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age: >74 years vs ≤ 74 years | 1.49 (0.57–3.69) | 0.3986 | | |
| Sex: Male vs Female | 0.65 (0.26–1.69) | 0.3596 | | |
| Vascular invasion: Present vs Absent | 3.07 (0.64–55.22) | 0.1936 | | |
| TIL: Low vs High | 1.94 (0.77–4.86) | 0.1575 | | |
| MSI: Present vs Absent | 2.07 (0.79–5.39) | 0.1338 | | |
| TNM stage: II vs III | 0.39 (0.15–0.97) | 0.0425 | 0.36 (0.13–0.89) | 0.026 |
| <i>LGR5</i> : High vs Low | 3.18 (1.24–8.39) | 0.0161 | 3.48 (1.36–9.22) | 0.01 |

Figures




Figure 1

Representative images of LGR5 and EBV Representative features in LGR5-high expression (A and B) and LGR5-low expression (D and E) cases. LGR5-high expression cases show EBV negativity (C). LGR5-low expression cases show EBV positivity (F). (A and D, HE; B and E, LGR5; C and F, EBV).




Figure 2

Prognostic value of LGR5 in PD-AC by Kaplan–Meier analysis. A significant difference was found in OS between PD-AC cases in the LGR5-high expression group [median OS; 756 (range; 154.5–1306.5) days] and LGR5-low expression [median OS; 1338 (range; 922.75–2022.75) days; log-rank test, P=0.0108].